Customized Crosslinking: Safety and Efficacy in an Epithelium-off Accelerated-pulsated Protocol for Thin Keratoconus

NCT ID: NCT06159881

Last Updated: 2023-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to document corneal ectasia stability in patients with keratoconus diagnosis treated with personalized cross linking energy. The main questions it aims to answer are:

* Is it effective while using personalized (reduced) energy?
* Is it safe for corneas thinner than 400 microns? Participants will be treated with personalized energy corneal cross linking and posteriorly, will attend subsequent follow-up consults

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keratoconus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Progression Customized Cross-Linking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Personalized cross linking

Participants were treated with personalized energy cross linking according to their thinnest point corneal pachymetry

Group Type EXPERIMENTAL

Corneal Cross Linking

Intervention Type PROCEDURE

Total fluence adapted to thinnest point pachymetry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Corneal Cross Linking

Total fluence adapted to thinnest point pachymetry

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Keratoconus diagnosed with corneal tomography/topography
* Thinnest point pachymetry below 400 microns

Exclusion Criteria

* Previous corneal cross linking history
* Corneal scars not allowing best corrected visual acuity of 20/100 or better
* Previous corneal hydrops history
* Psychomotor retardation history
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Oftalmología Fundación Conde de Valenciana

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Enrique Graue, MD, MSc

Role: STUDY_DIRECTOR

Instituto de Oftalmología Conde de Valenciana

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto de Oftalmología Conde de Valenciana

Mexico City, , Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Itamar Vigderovich, MD

Role: CONTACT

Phone: +52 5519491905

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Enrique Graue

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Hafezi F, Kling S, Gilardoni F, Hafezi N, Hillen M, Abrishamchi R, Gomes JAP, Mazzotta C, Randleman JB, Torres-Netto EA. Individualized Corneal Cross-linking With Riboflavin and UV-A in Ultrathin Corneas: The Sub400 Protocol. Am J Ophthalmol. 2021 Apr;224:133-142. doi: 10.1016/j.ajo.2020.12.011. Epub 2021 Jan 30.

Reference Type BACKGROUND
PMID: 33340508 (View on PubMed)

Lang PZ, Hafezi NL, Khandelwal SS, Torres-Netto EA, Hafezi F, Randleman JB. Comparative Functional Outcomes After Corneal Crosslinking Using Standard, Accelerated, and Accelerated With Higher Total Fluence Protocols. Cornea. 2019 Apr;38(4):433-441. doi: 10.1097/ICO.0000000000001878.

Reference Type BACKGROUND
PMID: 30681515 (View on PubMed)

Nath S, Shen C, Koziarz A, Banfield L, Nowrouzi-Kia B, Fava MA, Hodge WG. Transepithelial versus Epithelium-off Corneal Collagen Cross-linking for Corneal Ectasia: A Systematic Review and Meta-analysis. Ophthalmology. 2021 Aug;128(8):1150-1160. doi: 10.1016/j.ophtha.2020.12.023. Epub 2020 Dec 28.

Reference Type BACKGROUND
PMID: 33383093 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17 CI 09 015 008

Identifier Type: -

Identifier Source: org_study_id